Weise, WJ, Hermance, ME, Forrester, NL, Adams, AP, Langsjoen, R, Gorchakov, R, Wang, E, Alcorn, MDH, Tsetsarkin, K and Weaver, SC (2014) A novel live-attenuated vaccine candidate for mayaro Fever. PLoS Neglected Tropical Diseases, 8. e2969 - e2969.

[img]
Preview
Text
journal.pntd.0002969.PDF - Published Version
Available under License Creative Commons Attribution.

Download (902kB) | Preview

Abstract

Mayaro virus (MAYV) is an emerging, mosquito-borne alphavirus that causes a dengue-like illness in many regions of South America, and which has the potential to urbanize. Because no specific treatment or vaccine is available for MAYV infection, we capitalized on an IRES-based approach to develop a live-attenuated MAYV vaccine candidate. Testing in infant, immunocompetent as well as interferon receptor-deficient mice demonstrated a high degree of attenuation, strong induction of neutralizing antibodies, and efficacy against lethal challenge. This vaccine strain was also unable to infect mosquito cells, a major safety feature for a live vaccine derived from a mosquito-borne virus. Further preclinical development of this vaccine candidate is warranted to protect against this important emerging disease.

Item Type: Article
Additional Information: Copyright: 2014 Weise et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Uncontrolled Keywords: live-attenuated vaccine, mayaro fever.
Subjects: R Medicine > R Medicine (General)
R Medicine > R Medicine (General) > R735 Medical education. Medical schools. Research
Divisions: Faculty of Natural Sciences > School of Life Sciences
Depositing User: Symplectic
Date Deposited: 26 Feb 2020 12:54
Last Modified: 26 Feb 2020 12:54
URI: http://eprints.keele.ac.uk/id/eprint/7701

Actions (login required)

View Item View Item